Influenza vaccine (quadrivalent)

The quadrivalent influenza vaccine is designed to protect against four different strains of the flu virus and is a key tool in preventing seasonal influenza, which can lead to severe illness and complications, especially in vulnerable populations. Studies have demonstrated that quadrivalent vaccines are effective in reducing the incidence of influenza across various age groups. For instance, high-dose versions of these vaccines have been shown to provide better immune responses and protection in older adults compared to standard doses. Additionally, mRNA-based quadrivalent vaccines have also shown promise in early trials for their safety and ability to elicit strong immune responses.

The vaccine is particularly important for individuals with high-risk cardiovascular disease, as it can reduce the risk of cardiopulmonary hospitalization and mortality. Despite these findings, more research is needed to fully understand the long-term efficacy and potential side effects of quadrivalent influenza vaccines in diverse populations.

Sources

• Quadrivalent influenza vaccine (Sinovac Biotech) for seasonal influenza prophylaxis. (PMID:33434084)
• High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults. (PMID:32578447)
• Quadrivalent inactivated influenza vaccine (VaxigripTetra™). (PMID:29157068)
• Fluarix quadrivalent vaccine for influenza. (PMID:26098443)
• A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. (PMID:39919447)
• Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. (PMID:33275134)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._